Clopidogrel in the management of cerebrovascular events

International Journal of Clinical Practice

Volumn 58, Issue 4, 2004, Pages 402-410

  Ringleb, Peter A ^a   Schellinger, P D ^a   Schwark, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiplatelets; Clopidogrel; Secondary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PLACEBO; TELMISARTAN; TICLOPIDINE; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INDIGESTION; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; VOMITING;

ARTERIOSCLEROSIS; ASPIRIN; CEREBROVASCULAR ACCIDENT; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; THROMBOSIS; TICLOPIDINE;

EID: 2642512994     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00177.x     Document Type: Review

References (44)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326 (4): 242-50.
2. Caplan LR. Diagnosis and treatment of ischemic stroke. JAMA 1991; 266 (17): 2413-8.
3. Grau AJ, Weimar C, Buggle F et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32 (11): 2559-66.
4. Bronnum-Hansen H, Davidsen M, Thorvaldsen P. Long-term survival and causes of death after stroke. Stroke 2001; 32 (9): 2131-6.
5. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 1990; 82 (6): 1925-31.
6. 0 Heart and Stroke Statistical Update. American Heart Association, Dallas: 1999.
7. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
8. Savi P, Combalbert J, Gaich C et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72 (2): 313-7.
9. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86.
10. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66 (2): 255.
11. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
12. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000; 2: CD001246.
13. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103 (3): 363-8.
14. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90 (6): 625-8.
15. Bhatt DL, Foody JM, Hirsch AT, Ringleb P, Hacke W, Topol EJ. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol 2000; 35 (Suppl. A): 326.
16. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35 (2): 528-32.
17. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339 (23): 1665-71.
18. Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98 (16): 1597-603.
19. Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334 (17): 1084-9.
20. Berger PB. Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Curr Control Trials Cardiovasc Med 2000; 1 (2): 83-7.
21. Müller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101 (6): 590-3.
22. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102 (6): 624-9.
23. Yusuf S, Zhao F, Mehta S et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndroms without SW-segment elevation. N Engl J Med 2001; 345: 494-502.
24. Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19): 2411-20.
25. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-33.
26. Peters R, Zao F, Lewis B, Fox K, Yusuf S. Aspirin dose and bleeding events in the CURE study. Eur Heart J 2002; 23 (abst suppl): 510.
27. Teal PA. Recent Clinical Trial Results with Antiplatelet Therapy: Implications in Stroke Prevention. Cerebrovasc Dis 2004; 17 (Suppl. 3): 6-10.
28. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: Dipyridamole and acetyl-salicyclic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
29. Bennett CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342 (24): 1773-7.
30. Clopidogrel (Plavix) [package insert]. Bristol-Myers Squibb and Sanofi-Synthelabo, New York, NY: May 2002.
31. Majhail NS, Lichtin AE. Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality. Cleve Clin J Med 2003; 70 (5): 466-70.
32. Zakarija A, Bandarenko N, Pandey DK et al. Clopidogrel-associated TTP. An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the food and drug administration. Stroke 2004.
33. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31 (1): 53-9.
34. Müller I, Massberg S, Zierhut W et al. Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB). Pathophysiol Haemost Thromb 2002; 32 (1): 16-24.
35. Gaspoz JM, Coxson PG, Goldman PA et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346 (23): 1800-6.
36. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002; 13 (Suppl. 1): 1-6.
37. Hankey GJ, Eikelboom JW. Antiplatelet Drugs. Med J Aust 2003; 178 (11): 568-74.
38. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89 (3): 1333-445.
39. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994; 1 (4): 333-9.
40. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992; 49 (8): 857-63.
41. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326 (6): 381-6.
42. Coukell AJ, Markhan A. Clopidogrel. Drugs 1997; 54: 745-50.
43. Hankey GJ. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Cerebrovasc Dis 2004; 17 (Suppl. 3): 11-6.
44. (www.strokecenter.org/trials).